Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2022 | Associations between neuropsychiatric symptoms and the progression of Alzheimer’s disease

Corinne Fischer • 30 Mar 2022
AAN 2022
Alzheimer’s Disease Dementia

Corinne Fischer, MD, University of Toronto, Toronto, Canada, discusses how the appearance of neuropsychiatric symptoms before the onset of Alzheimer’s disease and at various stages in the progression of the disease can be an indicator of the severity of the disease. An improved understanding of mild behavioral impairment (MBI) has shown that an early appearance of neuropsychiatric symptoms, without cognitive problems, could be an early warning sign of the development of neurodegenerative disease. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.

More from Corinne Fischer

Comparison of diagnostic criteria for dementia-related psychosis
3:06
Comparison of diagnostic criteria for dementia-related psychosis
Corinne Fischer • 30 Mar 2022
Mechanisms behind development of neuropsychiatric symptoms in Alzheimer’s disease
1:28
Mechanisms behind development of neuropsychiatric symptoms in Alzheimer’s disease
Corinne Fischer • 30 Mar 2022
Future research directions for neuropsychiatric symptoms in Alzheimer's disease
2:07
Future research directions for neuropsychiatric symptoms in Alzheimer's disease
Corinne Fischer • 30 Mar 2022

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals